Metagenomi Stock

metagenomi.coHealthcare / BioTech & PharmaFounded: 2018

Metagenomi is a research and development biotech company focused on gene editing and gene therapy to treat human diseases and other ailments. The private company partners with scientists and field experts to develop gene editing systems that are derived from elements found in nature.

Register for Details

For more details on financing and valuation for Metagenomi, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for Metagenomi.

Register Today

Metagenomi investors also invested in these private companies

Team

Management Team

Brian C. Thomas, PhD
Founder and Chief Executive Officer
Alan Cohen, MD
Chief Medical Officer and SVP of Monogenic Diseases
Jian Irish, PhD.
President and Chief Operating Officer
Simon Harnest, MSc
Chief Investment Officer and SVP of Strategy

Board Members

Jürgen Eckhardt, MD, MBA
Bayer
Sebastian Bernales, PhD
Hum­boldt Fund
Willard H. Dere, MD
University of Utah
Risa Stack, PhD
The Production Board
Santhosh Palani, PhD, CFA
PFM Data Sciences

Other companies like Metagenomi in the BioTech & Pharma sector

Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$8.45B
Sector
Last Round Est. Valuation
$500MM
Sector
Last Round Est. Valuation
$8.84B
Sector
Last Round Est. Valuation
$1.01B
Sector
Last Round Est. Valuation
$303.94MM
Sector
Last Round Est. Valuation
$4.74B

News Highlights

Metagenomi Closes Oversubscribed Series B Financing Totaling $275M to Advance Lead Therapeutic Programs into Clinical Development and Grow Genetic Medicines Pipeline
$100M Series B extension financing co-led by Novo Holdings A/S, Catalio Capital Management and SymBiosis, with participation from new and existing investors, including Leaps by Bayer and Moderna, as well as the initial Series B leads PFM Health Sciences, Farallon Capital Management, and a leading global investment firm.
Updated on: Sep 24, 2023